EUVIMEDEUVIMED entdecken
CrossrefInfokarte

Population-based assessment of treatment patterns for high-risk localized prostate cancer

Christopher J.D. Wallis, Shawn Malone, Ilias Cagiannos, Robert J. Hamilton, Naveen S. Basappa, Cristiano Ferrario, Geoffrey T. Gotto, Ricardo Fernandes, Tamim Niazi, Christopher Morash, Ricardo A. Rendon, Fred Saad, Sebastien J. Hotte, Eva Sulatycki, Anousheh Zardan, Bobby Shayegan

Canadian Urological Association Journal · 2026-10-19 · 21 (2)

DOI: 10.5489/cuaj.9712 ↗
AbstractBibliografische Angaben

Abstract

Introduction: High- and very high-risk (H/vHR) localized and locally advanced prostate cancer (LPCa) carry a high burden of distant relapse. In light of emerging data on adjunctive systemic therapy, we aimed to assess present-day, real-world treatment patterns and outcomes among Canadian patients with intermediate-risk (IR) and H/vHR LPCa. Methods: This retrospective, population-based cohort study identified men aged ≥18 years diagnosed with LPCa between 2010 and 2022 in Ontario, Canada. Patients were stratified into IR and H/vHR groups. Baseline patient characteristics and treatment patterns following LPCa diagnosis were described. Clinical outcomes, including median time to mortality, were assessed using Kaplan-Meier analyses. To better characterize androgen deprivation therapy (ADT) exposure, subgroup analyses were performed in patients aged ≥66 years. Results: Among 31 571 eligible patients, 18 365 had IR LPCa and 13 206 had H/vHR LPCa. Within one year from diagnosis, patients with H/vHR were more likely to receive definitive therapy (95.4% vs. 81.5%), with shorter durations between diagnosis and treatment (median 72 days vs. 92 days) compared to patients with IR. Patients with H/vHR demonstrated lower median time to mortality (median 4.9 vs. 5.9 years, p

Wissen, das zu Ihrer Arbeit passt.

Vom kostenlosen Einstieg über die persönliche Recherche bis zur vollständigen Research Suite.

Tarife ansehen →

Sind alle Verlagsvolltexte enthalten?

Nein. Bibliografische Nachweise, Abstracts und Volltexte sind unterschiedliche Inhalte. Ob ein Volltext verfügbar ist, hängt von der Quelle, Open Access und Ihren vorhandenen Lizenzen ab. Ein EUVIMED-Tarif ersetzt keine zusätzlichen Verlagsrechte.

Tarife ansehen →